Title | Cardiac Arrhythmias: New Therapeutic Drugs and Devices [electronic resource] : Proceedings of the Symposium on New Drugs and Devices, held at Philadelphia, PA October 4 and 5, 1984 / edited by Joel Morganroth, E. Neil Moore |
---|---|
Imprint | Boston, MA : Springer US, 1985 |
Connect to | http://dx.doi.org/10.1007/978-1-4613-2595-6 |
Descript | XII, 356 p. online resource |
I Basic Considerations -- 1 What animal models are useful in selecting new antiarrhythmic drugs? -- 2 How to test for antiarrhythmic drugs -- 3 Initial evaluation of new antiarrhythmic agents in man: normal volunteers or patients? -- 4 Is there a rational basis for the modified classification of antiarrhythmic drugs? -- Panel Discussion: Basic considerations -- II Status of Specific Antiarrhythmic Agents -- 5 Procainamide, Quinidine, Disopyramide, Cibenzoline, Pirmenol โ efficacy in the treatment of ventricular arrhythmias: current status and controversies -- 6 Mexiletine, Tocainide and Ethmozine: newer class I antiarrhythmic agents -- 7 Class IC antiarrhythmic agents: status โ 1984 -- 8 Role of beta-blocking agents in the treatment of ventricular arrhythmias -- 9 Status of class III antiarrhythmic drugs: Amiodarone, Bretylium and Sotalol -- Panel Discussion: Status of specific antiarrhythmic agents -- III Special Considerations and FDA Standards -- 10 Some thoughts on efficacy trials of antiarrhythmic agents: pitfalls of mimicking clinical practice -- 11 Use of a computer in the new drug evaluation process -- 12 Sudden cardiac death โ failure or effect of antiarrhythmic drug therapy? -- 13 Sudden death as an end-point for the clinical evaluation of antiarrhythmic drugs -- 14 Holter/exercise and electrophysiologic methods forevaluating drug therapy for malignant ventricular arrhythmias: do we need both models? -- Panel Discussion: Special considerations and FDA standards -- IV New Antiarrhythmic Devices -- 15 DVI vs DDD pacemakers - proarrhythmic or antiarrhythmic? -- 16 Pacing for ventricular tachycardia -- 17 Termination of ventricular tachycardia by transvenous cardioversion -- 18 The automatic implantable cardioverter/defibrillator -- 19 New antiarrhythmia devices โ FDAโs requirements for effectiveness -- Panel Discussion: New antiarrhythmic devices -- V Evaluation Of Atrial Arrhythmias -- 20 Study designs to evaluate atrial arrhythmias are easy -- 21 Role of the autonomic nervous system in the generation of supraventricular tachyarrhythmias: clues to drug selection -- 22 Approaches to drug selection and serial drug testing -- Panel Discussion: Evaluation of atrial arrhythmias -- Participants